Steven Haney, PhD
Research Director, Pharmaceutical Biotechnology Center
Steven Haney, Ph.D., joined the IBRI in July 2018 as Research Fellow in the IBRI’s Pharmaceutical Biotechnology Center. In his role as Research Director, he is responsible for establishing the protein expression and production cores, as well as developing biological support for emerging therapeutics.
Prior to the IBRI, and since 2012, Dr. Haney served as a Senior Research Advisor and Group Leader, and Senior Research Advisor at Eli Lilly and Company, Indianapolis, IN. His research focus at Lilly was on quantitative biology discovery chemistry and research technologies, and oncology translational research. Prior to Lilly, he was a consultant to the Yale Medical Center for Molecular Discovery, New Haven, CT. He also held various senior, principal and management scientific research positions at Pfizer Research and Wyeth Research, both Cambridge, MA, and at Cadus Pharmaceutical Corporation, Tarrytown, NY.
Dr. Haney earned a B.S. in Biochemistry from the State University of New York, Stony Brook, NY, and a Ph.D., in Biological Chemistry from the University of Michigan, Ann Arbor, MI and was a Research Fellow in the Department of Molecular Biology at Princeton University, Princeton, NJ. He co-holds the patent for methods of modulating apoptosis using inhibitors of brain-localized protein kinases. He has authored or co-authored more than 25 publications, and has authored more than 30 commentaries, reviews and book chapters, and is the editor of two books on High Content Screening. He is currently President of the Society for Biomolecular Imaging and Informatics.